Compliance and tolerability of subcutaneous hepatitis b immunoglobulin self-administration in liver transplant patients: A prospective, observational, multicenter study

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 677-684

  Klein, Christian Georg ^a   Cicinnati, Vito ^a,b   Schmidt, Hartmut ^b   Ganten, Tom ^c   Scherer, Marcus N ^d   Braun, Felix ^e   Zeuzem, Stefan ^f   Wartenberg Demand, Andrea ^g   Niemann, Gabriele ^g   Schmeidl, Rainer ^g   Beckebaum, Susanne ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g BIOTEST AG   (Germany)

Author keywords

Compliance; HBIg; HBV; Home; Self injection; Subcutaneous

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TENOFOVIR;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HEMATOMA; HEPATITIS B; HUMAN; ISCHEMIA; KIDNEY DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; OBSERVATIONAL STUDY; OROPHARYNX PAIN; PATIENT COMPLIANCE; PROSPECTIVE STUDY; REINFECTION; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UREA BLOOD LEVEL;

ADULT; AGED; FEMALE; HEPATITIS B; HUMANS; HYPODERMOCLYSIS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84890863869     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.889269     Document Type: Article

References (20)

1. Jiang L, Yan L-N: Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroent, 2010; 16: 2468-75
2. Chen J, Yi L, Jia JD et al: Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J Gastroenterol Hepatol, 2010; 25: 872-79
3. Cholongitas E, Goulis J, Akriviadis E, Paptheodoridis GV: Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl, 2011; 17: 1176-90
4. Buchanan C, Tran TT: Current status of liver transplantation for hepatitis B virus. Clin Liver Dis, 2011; 15: 753-64
5. Yataco M, Bonatti H, Machicao V et al: Long term survival and complications after liver transplantation in patients with chronic hepatitis B. Ann Transplant, 2010; 15: 27-34
6. Burra P, Senzolo M, Adam R et al., ELITA; ELTR Liver Transplant Centers: Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant, 2010; 10: 138-48
7. Congly SE, Burak KW, Coffin CS: Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. Expert Rev, 2011; 7: 429-36
8. Faust D, Rabenau HF, Allwinn R et al: Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant, 2003; 17: 254-58
9. Angus PW, McCaughan GW, Gane EJ et al: Combination low-dose hepatitis B immune globulinand lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl, 2000; 6: 429-33
10. Gane EJ, Angus PW, Strasser S et al., Australasian Liver Transplant Study Group: Lamivudine plus low-dose hepatitis B immunoglobulinto prevent recurrent hepatitis B following liver transplantation. Gastroenterology, 2007; 132: 931-37
11. Hooman N, Rifai K, Hadem J et al: Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl, 2008; 14: 435-42
12. Marzano A, Marengo A, Andreone P et al: Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. Minerva Med, 2010; 101: 373-83
13. Filipponi F, Franchello A, Carrai P et al: Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. Dig Liver Dis, 2010; 42: 509-14
14. Degertekin B, Han SH, Keeffe EB et al: Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant, 2010; 10: 1823-33
15. Franciosi M, Caccamo L, De Simone P et al., TWINS I Study Group: Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis onthe quality of life of liver transplant recipients. Liver Transpl, 2012; 18: 332-39
16. Singham J, Greanya ED, Lau K et al: Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxisagainst hepatitis B recurrence. Ann Hepatol, 2010; 9: 166-71
17. Thurmann PA, Szymanski J, Haffner S et al: Pharmacokinetics and safety of a novel anti-HBsenriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol, 2006; 62: 511-12
18. Yahyazadeh A, Beckebaum S, Cicinnati V et al: Efficacy and safety of subcutaneous human HBVimmunoglobulin (ZutectraR) in liver transplantation: an open, prospective, single-arm Phase II study. Transplant Int, 2011; 24: 441-50
19. Committee for Medicinal Products for Human Use. Guideline on the core SPC for human plasma derived hepatitis-B immunoglobulin for intravenous use (CPMP/BPWG/4027/02) http://www.ema.europa.eu/docs Accessed 21 February 2013
20. Di Costanzo GG, Lanza AG, Picciotto FP et al: Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study. Am J Transplant, 2013; 13: 348-52